Some Haemonetics Corporation (NYSE:HAE) shareholders may be a little concerned to see that the CEO, President & Director, Christopher Simon, recently sold a whopping US$7.0m worth of stock at a price of US$137 per share. That sale reduced their total holding by 16.6% which is hardly insignificant, but far from the worst we’ve seen.
Check out our latest analysis for Haemonetics
The Last 12 Months Of Insider Transactions At Haemonetics
In fact, the recent sale by CEO, President & Director Christopher Simon was not their only sale of Haemonetics shares this year. They previously made an even bigger sale of -US$7.0m worth of shares at a price of US$137 per share. So we know that an insider sold shares at around the present share price of US$130. While we don’t usually like to see insider selling, it’s more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it’s not too bad (but it’s still not a positive).
We note that in the last year insiders divested 167k shares for a total of US$19m. Haemonetics insiders didn’t buy any shares over the last year. You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
Does Haemonetics Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 0.9% of Haemonetics shares, worth about US$60m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About Haemonetics Insiders?
Insiders sold Haemonetics shares recently, but they didn’t buy any. And even if we look to the last year, we didn’t see any purchases. But it is good to see that Haemonetics is growing earnings. While insiders do own shares, they don’t own a heap, and they have been selling. We’d think twice before buying! Of course, the future is what matters most. So if you are interested in Haemonetics, you should check out this free report on analyst forecasts for the company.
Of course Haemonetics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.